+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Malabsorption Syndrome Market by Disease Type, Treatment Type, Distribution Channel, End User, Age Group - Global Forecast to 2030- Product Image
Malabsorption Syndrome Market by Disease Type, Treatment Type, Distribution Channel, End User, Age Group - Global Forecast to 2030- Product Image
Sale

Malabsorption Syndrome Market by Disease Type, Treatment Type, Distribution Channel, End User, Age Group - Global Forecast to 2030

  • PDF Icon

    Report

  • 193 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5674664
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The malabsorption syndrome market is evolving rapidly as healthcare providers, biopharma companies, and policy leaders adapt to new treatment paradigms and shifting patient needs. Senior decision-makers require actionable market intelligence to navigate a landscape shaped by innovation, regulatory change, and operational pressures.

Market Snapshot: Malabsorption Syndrome Market Performance

The Malabsorption Syndrome Market grew from USD 2.49 billion in 2024 to USD 2.63 billion in 2025. It is expected to continue growing at a CAGR of 5.59%, reaching USD 3.45 billion by 2030. This expansion reflects rising prevalence of related conditions, increasing awareness, and ongoing innovation in therapeutic development and delivery.

Scope & Segmentation

This report offers a comprehensive analysis, structured to empower effective strategy development. The segmentation covers every significant facet of the malabsorption syndrome market:

  • Disease Types: Celiac Disease, Crohn's Disease, Lactose Intolerance, Pancreatic Insufficiency, Short Bowel Syndrome, Tropical Sprue
  • Treatment Types: Dietary Management, Enzyme Supplements (Lactase Enzymes - Powder Form, Tablet Form; Pancreatic Enzymes - Microbial Derived, Porcine Derived), Pharmaceuticals (H2 Receptor Blockers; Proton Pump Inhibitors - Esomeprazole, Omeprazole), Probiotics
  • Distribution Channels: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies
  • End Users: Clinics, Home Care Settings, Hospitals, Research Institutes
  • Age Groups: Adult, Geriatric, Pediatric
  • Regions: Americas (including U.S., Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (covering both established and emerging markets such as United Kingdom, Germany, France, Russia, United Arab Emirates, Saudi Arabia, and South Africa), Asia-Pacific (featuring growth economies like China, India, Japan, Australia, South Korea, and Southeast Asian countries)
  • Companies Profiled: AbbVie Inc., Nestlé S.A., Danone S.A., Reckitt Benckiser Group plc, Baxter International Inc., Abbott Laboratories, Fresenius Kabi AG, Siemens Healthineers AG, Roche Diagnostics International Ltd., BioMérieux S.A.

Key Takeaways for Senior Decision-Makers

  • Heightened clinical awareness and diagnostic advances drive early detection and tailored patient care approaches across regions.
  • Integration of precision nutrition, real-world evidence, and patient-reported outcomes informs more personalized treatment protocols and supports recurring innovation.
  • Therapeutic development increasingly leverages technologies such as digital health, telemedicine, and advanced genomic profiling to refine intervention and monitoring.
  • Regulatory harmonization in core regions is accelerating product approvals and expanding patient access, while local pricing pressures influence product adoption strategies.
  • Portfolio diversification, enabled by acquisitions, partnerships, and internal R&D, allows leading companies to address both high-prevalence and rare conditions effectively.
  • Enhanced focus on post-market surveillance and outcomes research strengthens the case for broader payer coverage through evidence of long-term benefit.

Tariff Impact: U.S. Policy and Global Supply Chain Adaptation

In 2025, new U.S. tariffs affected global sourcing and manufacturing for malabsorption therapies. Import duties on active ingredients and packaging led producers to develop domestic supply partnerships or invest in local facilities. The result: increased wholesale prices and restructured insurance reimbursement, with some organizations optimizing operations to maintain product accessibility without excessive cost transfers to end users. Maintaining agile supply chains and engaging in ongoing scenario planning has become essential for stakeholders mitigating evolving trade risks.

Malabsorption Syndrome Market: Methodology & Data Sources

This report applies a rigorous blend of secondary research—industry literature, regulatory databases, and medical journals—and primary interviews with clinicians, supply chain experts, and market leaders. Findings are verified through triangulation with proprietary databases and advanced analytical modeling to ensure comprehensive accuracy.

Why This Report Matters: Strategic Outcomes

  • Enables senior leaders to assess growth opportunities, anticipate regulatory and trade impacts, and shape evidence-based strategies for portfolio development and market expansion.
  • Provides a holistic segmentation view supporting targeted resource allocation and tailored engagement in high-potential clinical and regional segments.
  • Empowers stakeholder decision-making with validated, actionable insights grounded in the latest real-world and market-driven research.

Conclusion

This analysis equips healthcare decision-makers with strategic clarity to respond to evolving clinical, technological, and policy trends. Forward-focused strategies and robust operational agility remain key for long-term market success in malabsorption syndromes.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Malabsorption Syndrome Market, by Disease Type
8.1. Introduction
8.2. Celiac Disease
8.3. Crohn's Disease
8.4. Lactose Intolerance
8.5. Pancreatic Insufficiency
8.6. Short Bowel Syndrome
8.7. Tropical Sprue
9. Malabsorption Syndrome Market, by Treatment Type
9.1. Introduction
9.2. Dietary Management
9.3. Enzyme Supplements
9.3.1. Lactase Enzymes
9.3.1.1. Powder Form
9.3.1.2. Tablet Form
9.3.2. Pancreatic Enzymes
9.3.2.1. Microbial Derived
9.3.2.2. Porcine Derived
9.4. Pharmaceuticals
9.4.1. H2 Receptor Blockers
9.4.2. Proton Pump Inhibitors
9.4.2.1. Esomeprazole
9.4.2.2. Omeprazole
9.5. Probiotics
10. Malabsorption Syndrome Market, by Distribution Channel
10.1. Introduction
10.2. Hospital Pharmacies
10.3. Online Pharmacies
10.4. Retail Pharmacies
11. Malabsorption Syndrome Market, by End User
11.1. Introduction
11.2. Clinics
11.3. Home Care Settings
11.4. Hospitals
11.5. Research Institutes
12. Malabsorption Syndrome Market, by Age Group
12.1. Introduction
12.2. Adult
12.3. Geriatric
12.4. Pediatric
13. Americas Malabsorption Syndrome Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Malabsorption Syndrome Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Malabsorption Syndrome Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. AbbVie Inc.
16.3.2. Nestlé S.A.
16.3.3. Danone S.A.
16.3.4. Reckitt Benckiser Group plc
16.3.5. Baxter International Inc.
16.3.6. Abbott Laboratories
16.3.7. Fresenius Kabi AG
16.3.8. Siemens Healthineers AG
16.3.9. Roche Diagnostics International Ltd.
16.3.10. BioMérieux S.A.
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. MALABSORPTION SYNDROME MARKET MULTI-CURRENCY
FIGURE 2. MALABSORPTION SYNDROME MARKET MULTI-LANGUAGE
FIGURE 3. MALABSORPTION SYNDROME MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 12. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY AGE GROUP, 2024 VS 2030 (%)
FIGURE 16. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS MALABSORPTION SYNDROME MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS MALABSORPTION SYNDROME MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES MALABSORPTION SYNDROME MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES MALABSORPTION SYNDROME MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA MALABSORPTION SYNDROME MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA MALABSORPTION SYNDROME MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC MALABSORPTION SYNDROME MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC MALABSORPTION SYNDROME MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. MALABSORPTION SYNDROME MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. MALABSORPTION SYNDROME MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. MALABSORPTION SYNDROME MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY CELIAC DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY CROHN'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY LACTOSE INTOLERANCE, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY PANCREATIC INSUFFICIENCY, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY SHORT BOWEL SYNDROME, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY TROPICAL SPRUE, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY DIETARY MANAGEMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY ENZYME SUPPLEMENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY LACTASE ENZYMES, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY POWDER FORM, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY TABLET FORM, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY LACTASE ENZYMES, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY PANCREATIC ENZYMES, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY MICROBIAL DERIVED, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY PORCINE DERIVED, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY PANCREATIC ENZYMES, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY ENZYME SUPPLEMENTS, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY PHARMACEUTICALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY H2 RECEPTOR BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY PROTON PUMP INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY ESOMEPRAZOLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY OMEPRAZOLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY PROBIOTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 47. AMERICAS MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 48. AMERICAS MALABSORPTION SYNDROME MARKET SIZE, BY ENZYME SUPPLEMENTS, 2018-2030 (USD MILLION)
TABLE 49. AMERICAS MALABSORPTION SYNDROME MARKET SIZE, BY LACTASE ENZYMES, 2018-2030 (USD MILLION)
TABLE 50. AMERICAS MALABSORPTION SYNDROME MARKET SIZE, BY PANCREATIC ENZYMES, 2018-2030 (USD MILLION)
TABLE 51. AMERICAS MALABSORPTION SYNDROME MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 52. AMERICAS MALABSORPTION SYNDROME MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2030 (USD MILLION)
TABLE 53. AMERICAS MALABSORPTION SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 54. AMERICAS MALABSORPTION SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 55. AMERICAS MALABSORPTION SYNDROME MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 56. AMERICAS MALABSORPTION SYNDROME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 57. UNITED STATES MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 58. UNITED STATES MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 59. UNITED STATES MALABSORPTION SYNDROME MARKET SIZE, BY ENZYME SUPPLEMENTS, 2018-2030 (USD MILLION)
TABLE 60. UNITED STATES MALABSORPTION SYNDROME MARKET SIZE, BY LACTASE ENZYMES, 2018-2030 (USD MILLION)
TABLE 61. UNITED STATES MALABSORPTION SYNDROME MARKET SIZE, BY PANCREATIC ENZYMES, 2018-2030 (USD MILLION)
TABLE 62. UNITED STATES MALABSORPTION SYNDROME MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 63. UNITED STATES MALABSORPTION SYNDROME MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2030 (USD MILLION)
TABLE 64. UNITED STATES MALABSORPTION SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 65. UNITED STATES MALABSORPTION SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 66. UNITED STATES MALABSORPTION SYNDROME MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 67. UNITED STATES MALABSORPTION SYNDROME MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 68. CANADA MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 69. CANADA MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 70. CANADA MALABSORPTION SYNDROME MARKET SIZE, BY ENZYME SUPPLEMENTS, 2018-2030 (USD MILLION)
TABLE 71. CANADA MALABSORPTION SYNDROME MARKET SIZE, BY LACTASE ENZYMES, 2018-2030 (USD MILLION)
TABLE 72. CANADA MALABSORPTION SYNDROME MARKET SIZE, BY PANCREATIC ENZYMES, 2018-2030 (USD MILLION)
TABLE 73. CANADA MALABSORPTION SYNDROME MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 74. CANADA MALABSORPTION SYNDROME MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2030 (USD MILLION)
TABLE 75. CANADA MALABSORPTION SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 76. CANADA MALABSORPTION SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 77. CANADA MALABSORPTION SYNDROME MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 78. MEXICO MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 79. MEXICO MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 80. MEXICO MALABSORPTION SYNDROME MARKET SIZE, BY ENZYME SUPPLEMENTS, 2018-2030 (USD MILLION)
TABLE 81. MEXICO MALABSORPTION SYNDROME MARKET SIZE, BY LACTASE ENZYMES, 2018-2030 (USD MILLION)
TABLE 82. MEXICO MALABSORPTION SYNDROME MARKET SIZE, BY PANCREATIC ENZYMES, 2018-2030 (USD MILLION)
TABLE 83. MEXICO MALABSORPTION SYNDROME MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 84. MEXICO MALABSORPTION SYNDROME MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2030 (USD MILLION)
TABLE 85. MEXICO MALABSORPTION SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 86. MEXICO MALABSORPTION SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 87. MEXICO MALABSORPTION SYNDROME MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 88. BRAZIL MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 89. BRAZIL MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 90. BRAZIL MALABSORPTION SYNDROME MARKET SIZE, BY ENZYME SUPPLEMENTS, 2018-2030 (USD MILLION)
TABLE 91. BRAZIL MALABSORPTION SYNDROME MARKET SIZE, BY LACTASE ENZYMES, 2018-2030 (USD MILLION)
TABLE 92. BRAZIL MALABSORPTION SYNDROME MARKET SIZE, BY PANCREATIC ENZYMES, 2018-2030 (USD MILLION)
TABLE 93. BRAZIL MALABSORPTION SYNDROME MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 94. BRAZIL MALABSORPTION SYNDROME MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2030 (USD MILLION)
TABLE 95. BRAZIL MALABSORPTION SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 96. BRAZIL MALABSORPTION SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 97. BRAZIL MALABSORPTION SYNDROME MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 98. ARGENTINA MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 99. ARGENTINA MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 100. ARGENTINA MALABSORPTION SYNDROME MARKET SIZE, BY ENZYME SUPPLEMENTS, 2018-2030 (USD MILLION)
TABLE 101. ARGENTINA MALABSORPTION SYNDROME MARKET SIZE, BY LACTASE ENZYMES, 2018-2030 (USD MILLION)
TABLE 102. ARGENTINA MALABSORPTION SYNDROME MARKET SIZE, BY PANCREATIC ENZYMES, 2018-2030 (USD MILLION)
TABLE 103. ARGENTINA MALABSORPTION SYNDROME MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 104. ARGENTINA MALABSORPTION SYNDROME MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2030 (USD MILLION)
TABLE 105. ARGENTINA MALABSORPTION SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 106. ARGENTINA MALABSORPTION SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 107. ARGENTINA MALABSORPTION SYNDROME MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 108. EUROPE, MIDDLE EAST & AFRICA MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 109. EUROPE, MIDDLE EAST & AFRICA MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 110. EUROPE, MIDDLE EAST & AFRICA MALABSORPTION SYNDROME MARKET SIZE, BY ENZYME SUPPLEMENTS, 2018-2030 (USD MILLION)
TABLE 111. EUROPE, MIDDLE EAST & AFRICA MALABSORPTION SYNDROME MARKET SIZE, BY LACTASE ENZYMES, 2018-2030 (USD MILLION)
TABLE 112. EUROPE, MIDDLE EAST & AFRICA MALABSORPTION SYNDROME MARKET SIZE, BY PANCREATIC ENZYMES, 2018-2030 (USD MILLION)
TABLE 113. EUROPE, MIDDLE EAST & AFRICA MALABSORPTION SYNDROME MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 114. EUROPE, MIDDLE EAST & AFRICA MALABSORPTION SYNDROME MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2030 (USD MILLION)
TABLE 115. EUROPE, MIDDLE EAST & AFRICA MALABSORPTION SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 116. EUROPE, MIDDLE EAST & AFRICA MALABSORPTION SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 117. EUROPE, MIDDLE EAST & AFRICA MALABSORPTION SYNDROME MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 118. EUROPE, MIDDLE EAST & AFRICA MALABSORPTION SYNDROME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 119. UNITED KINGDOM MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 120. UNITED KINGDOM MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 121. UNITED KINGDOM MALABSORPTION SYNDROME MARKET SIZE, BY ENZYME SUPPLEMENTS, 2018-2030 (USD MILLION)
TABLE 122. UNITED KINGDOM MALABSORPTION SYNDROME MARKET SIZE, BY LACTASE ENZYMES, 2018-2030 (USD MILLION)
TABLE 123. UNITED KINGDOM MALABSORPTION SYNDROME MARKET SIZE, BY PANCREATIC ENZYMES, 2018-2030 (USD MILLION)
TABLE 124. UNITED KINGDOM MALABSORPTION SYNDROME MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 125. UNITED KINGDOM MALABSORPTION SYNDROME MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2030 (USD MILLION)
TABLE 126. UNITED KINGDOM MALABSORPTION SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 127. UNITED KINGDOM MALABSORPTION SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 128. UNITED KINGDOM MALABSORPTION SYNDROME MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 129. GERMANY MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 130. GERMANY MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 131. GERMANY MALABSORPTION SYNDROME MARKET SIZE, BY ENZYME SUPPLEMENTS, 2018-2030 (USD MILLION)
TABLE 132. GERMANY MALABSORPTION SYNDROME MARKET SIZE, BY LACTASE ENZYMES, 2018-2030 (USD MILLION)
TABLE 133. GERMANY MALABSORPTION SYNDROME MARKET SIZE, BY PANCREATIC ENZYMES, 2018-2030 (USD MILLION)
TABLE 134. GERMANY MALABSORPTION SYNDROME MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 135. GERMANY MALABSORPTION SYNDROME MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2030 (USD MILLION)
TABLE 136. GERMANY MALABSORPTION SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 137. GERMANY MALABSORPTION SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 138. GERMANY MALABSORPTION SYNDROME MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 139. FRANCE MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 140. FRANCE MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 141. FRANCE MALABSORPTION SYNDROME MARKET SIZE, BY ENZYME SUPPLEMENTS, 2018-2030 (USD MILLION)
TABLE 142. FRANCE MALABSORPTION SYNDROME MARKET SIZE, BY LACTASE ENZYMES, 2018-2030 (USD MILLION)
TABLE 143. FRANCE MALABSORPTION SYNDROME MARKET SIZE, BY PANCREATIC ENZYMES, 2018-2030 (USD MILLION)
TABLE 144. FRANCE MALABSORPTION SYNDROME MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 145. FRANCE MALABSORPTION SYNDROME MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2030 (USD MILLION)
TABLE 146. FRANCE MALABSORPTION SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 147. FRANCE MALABSORPTION SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 148. FRANCE MALABSORPTION SYNDROME MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 149. RUSSIA MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 150. RUSSIA MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 151. RUSSIA MALABSORPTION SYNDROME MARKET SIZE, BY ENZYME SUPPLEMENTS, 2018-2030 (USD MILLION)
TABLE 152. RUSSIA MALABSORPTION SYNDROME MARKET SIZE, BY LACTASE ENZYMES, 2018-2030 (USD MILLION)
TABLE 153. RUSSIA MALABSORPTION SYNDROME MARKET SIZE, BY PANCREATIC ENZYMES, 2018-2030 (USD MILLION)
TABLE 154. RUSSIA MALABSORPTION SYNDROME MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 155. RUSSIA MALABSORPTION SYNDROME MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2030 (USD MILLION)
TABLE 156. RUSSIA MALABSORPTION SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 157. RUSSIA MALABSORPTION SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 158. RUSSIA MALABSORPTION SYNDROME MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 159. ITALY MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 160. ITALY MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 161. ITALY MALABSORPTION SYNDROME MARKET SIZE, BY ENZYME SUPPLEMENTS, 2018-2030 (USD MILLION)
TABLE 162. ITALY MALABSORPTION SYNDROME MARKET SIZE, BY LACTASE ENZYMES, 2018-2030 (USD MILLION)
TABLE 163. ITALY MALABSORPTION SYNDROME MARKET SIZE, BY PANCREATIC ENZYMES, 2018-2030 (USD MILLION)
TABLE 164. ITALY MALABSORPTION SYNDROME MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 165. ITALY MALABSORPTION SYNDROME MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2030 (USD MILLION)
TABLE 166. ITALY MALABSORPTION SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 167. ITALY MALABSORPTION SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 168. ITALY MALABSORPTION SYNDROME MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 169. SPAIN MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 170. SPAIN MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 171. SPAIN MALABSORPTION SYNDROME MARKET SIZE, BY ENZYME SUPPLEMENTS, 2018-2030 (USD MILLION)
TABLE 172. SPAIN MALABSORPTION SYNDROME MARKET SIZE, BY LACTASE ENZYMES, 2018-2030 (USD MILLION)
TABLE 173. SPAIN MALABSORPTION SYNDROME MARKET SIZE, BY PANCREATIC ENZYMES, 2018-2030 (USD MILLION)
TABLE 174. SPAIN MALABSORPTION SYNDROME MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 175. SPAIN MALABSORPTION SYNDROME MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2030 (USD MILLION)
TABLE 176. SPAIN MALABSORPTION SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 177. SPAIN MALABSORPTION SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 178. SPAIN MALABSORPTION SYNDROME MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 179. UNITED ARAB EMIRATES MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 180. UNITED ARAB EMIRATES MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 181. UNITED ARAB EMIRATES MALABSORPTION SYNDROME MARKET SIZE, BY ENZYME SUPPLEMENTS, 2018-2030 (USD MILLION)
TABLE 182. UNITED ARAB EMIRATES MALABSORPTION SYNDROME MARKET SIZE, BY LACTASE ENZYMES, 2018-2030 (USD MILLION)
TABLE 183. UNITED ARAB EMIRATES MALABSORPTION SYNDROME MARKET SIZE, BY PANCREATIC ENZYMES, 2018-2030 (USD MILLION)
TABLE 184. UNITED ARAB EMIRATES MALABSORPTION SYNDROME MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 185. UNITED ARAB EMIRATES MALABSORPTION SYNDROME MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2030 (USD MILLION)
TABLE 186. UNITED ARAB EMIRATES MALABSORPTION SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 187. UNITED ARAB EMIRATES MALABSORPTION SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 188. UNITED ARAB EMIRATES MALABSORPTION SYNDROME MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 189. SAUDI ARABIA MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 190. SAUDI ARABIA MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 191. SAUDI ARABIA MALABSORPTION SYNDROME MARKET SIZE, BY ENZYME SUPPLEMENTS, 2018-2030 (USD MILLION)
TABLE 192. SAUDI ARABIA MALABSORPTION SYNDROME MARKET SIZE, BY LACTASE ENZYMES, 2018-2030 (USD MILLION)
TABLE 193. SAUDI ARABIA MALABSORPTION SYNDROME MARKET SIZE, BY PANCREATIC ENZYMES, 2018-2030 (USD MILLION)
TABLE 194. SAUDI ARABIA MALABSORPTION SYNDROME MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 195. SAUDI ARABIA MALABSORPTION SYNDROME MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2030 (USD MILLION)
TABLE 196. SAUDI ARABIA MALABSORPTION SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 197. SAUDI ARABIA MALABSORPTION SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 198. SAUDI ARABIA MALABSORPTION SYNDROME MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 199. SOUTH AFRICA MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 200. SOUTH AFRICA MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 201. SOUTH AFRICA MALABSORPTION SYNDROME MARKET SIZE, BY ENZYME SUPPLEMENTS, 2018-2030 (USD MILLION)
TABLE 202. SOUTH AFRICA MALABSORPTION SYNDROME MARKET SIZE, BY LACTASE ENZYMES, 2018-2030 (USD MILLION)
TABLE 203. SOUTH AFRICA MALABSORPTION SYNDROME MARKET SIZE, BY PANCREATIC ENZYMES, 2018-2030 (USD MILLION)
TABLE 204. SOUTH AFRICA MALABSORPTION SYNDROME MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 205. SOUTH AFRICA MALABSORPTION SYNDROME MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2030 (USD MILLION)
TABLE 206. SOUTH AFRICA MALABSORPTION SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 207. SOUTH AFRICA MALABSORPTION SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 208. SOUTH AFRICA MALABSORPTION SYNDROME MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 209. DENMARK MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 210. DENMARK MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 211. DENMARK MALABSORPTION SYNDROME MARKET SIZE, BY ENZYME SUPPLEMENTS, 2018-2030 (USD MILLION)
TABLE 212. DENMARK MALABSORPTION SYNDROME MARKET SIZE, BY LACTASE ENZYMES, 2018-2030 (USD MILLION)
TABLE 213. DENMARK MALABSORPTION SYNDROME MARKET SIZE, BY PANCREATIC ENZYMES, 2018-2030 (USD MILLION)
TABLE 214. DENMARK MALABSORPTION SYNDROME MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 215. DENMARK MALABSORPTION SYNDROME MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2030 (USD MILLION)
TABLE 216. DENMARK MALABSORPTION SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 217. DENMARK MALABSORPTION SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 218. DENMARK MALABSORPTION SYNDROME MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 219. NETHERLANDS MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 220. NETHERLANDS MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 221. NETHERLANDS MALABSORPTION SYNDROME MARKET SIZE, BY ENZYME SUPPLEMENTS, 2018-2030 (USD MILLION)
TABLE 222. NETHERLANDS MALABSORPTION SYNDROME MARKET SIZE, BY LACTASE ENZYMES, 2018-2030 (USD MILLION)
TABLE 223. NETHERLANDS MALABSORPTION SYNDROME MARKET SIZE, BY PANCREATIC ENZYMES, 2018-2030 (USD MILLION)
TABLE 224. NETHERLANDS MALABSORPTION SYNDROME MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 225. NETHERLANDS MALABSORPTION SYNDROME MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2030 (USD MILLION)
TABLE 226. NETHERLANDS MALABSORPTION SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 227. NETHERLANDS MALABSORPTION SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 228. NETHERLANDS MALABSORPTION SYNDROME MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 229. QATAR MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 230. QATAR MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 231. QATAR MALABSORPTION SYNDROME MARKET SIZE, BY ENZYME SUPPLEMENTS, 2018-2030 (USD MILLION)
TABLE 232. QATAR MALABSORPTION SYNDROME MARKET SIZE, BY LACTASE ENZYMES, 2018-2030 (USD MILLION)
TABLE 233. QATAR MALABSORPTION SYNDROME MARKET SIZE, BY PANCREATIC ENZYMES, 2018-2030 (USD MILLION)
TABLE 234. QATAR MALABSORPTION SYNDROME MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 235. QATAR MALABSORPTION SYNDROME MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2030 (USD MILLION)
TABLE 236. QATAR MALABSORPTION SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 237. QATAR MALABSORPTION SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 238. QATAR MALABSORPTION SYNDROME MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 239. FINLAND MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 240. FINLAND MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 241. FINLAND MALABSORPTION SYNDROME MARKET SIZE, BY ENZYME SUPPLEMENTS, 2018-2030 (USD MILLION)
TABLE 242. FINLAND MALABSORPTION SYNDROME MARKET SIZE, BY LACTASE ENZYMES, 2018-2030 (USD MILLION)
TABLE 243. FINLAND MALABSORPTION SYNDROME MARKET SIZE, BY PANCREATIC ENZYMES, 2018-2030 (USD MILLION)
TABLE 244. FINLAND MALABSORPTION SYNDROME MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 245. FINLAND MALABSORPTION SYNDROME MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2030 (USD MILLION)
TABLE 246. FINLAND MALABSORPTION SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 247. FINLAND MALABSORPTION SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 248. FINLAND MALABSORPTION SYNDROME MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 249. SWEDEN MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 250. SWEDEN MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 251. SWEDEN MALABSORPTION SYNDROME MARKET SIZE, BY ENZYME SUPPLEMENTS, 2018-2030 (USD MILLION)
TABLE 252. SWEDEN MALABSORPTION SYNDROME MARKET SIZE, BY LACTASE ENZYMES, 2018-2030 (USD MILLION)
TABLE 253. SWEDEN MALABSORPTION SYNDROME MARKET SIZE, BY PANCREATIC ENZYMES, 2018-2030 (USD MILLION)
TABLE 254. SWEDEN MALABSORPTION SYNDROME MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 255. SWEDEN MALABSORPTION SYNDROME MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2030 (USD MILLION)
TABLE 256. SWEDEN MALABSORPTION SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 257. SWEDEN MALABSORPTION SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 258. SWEDEN MALABSORPTION SYNDROME MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 259. NIGERIA MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 260. NIGERIA MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 261. NIGERIA MALABSORPTION SYNDROME MARKET SIZE, BY ENZYME SUPPLEMENTS, 2018-2030 (USD MILLION)
TABLE 262. NIGERIA MALABSORPTION SYNDROME MARKET SIZE, BY LACTASE ENZYMES, 2018-2030 (USD MILLION)
TABLE 263. NIGERIA MALABSORPTION SYNDROME MARKET SIZE, BY PANCREATIC ENZYMES, 2018-2030 (USD MILLION)
TABLE 264. NIGERIA MALABSORPTION SYNDROME MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 265. NIGERIA MALABSORPTION SYNDROME MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2030 (USD MILLION)
TABLE 266. NIGERIA MALABSORPTION SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 267. NIGERIA MALABSORPTION SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 268. NIGERIA MALABSORPTION SYNDROME MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 269. EGYPT MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 270. EGYPT MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 271. EGYPT MALABSORPTION SYNDROME MARKET SIZE, BY ENZYME SUPPLEMENTS, 2018-2030 (USD MILLION)
TABLE 272. EGYPT MALABSORPTION SYNDROME MARKET SIZE, BY LACTASE ENZYMES, 2018-2030 (USD MILLION)
TABLE 273. EGYPT MALABSORPTION SYNDROME MARKET SIZE, BY PANCREATIC ENZYMES, 2018-2030 (USD MILLION)
TABLE 274. EGYPT MALABSORPTION SYNDROME MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 275. EGYPT MALABSORPTION SYNDROME MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2030 (USD MILLION)
TABLE 276. EGYPT MALABSORPTION SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 277. EGYPT MALABSORPTION SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 278. EGYPT MALABSORPTION SYNDROME MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 279. TURKEY MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 280. TURKEY MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 281. TURKEY MALABSORPTION SYNDROME MARKET SIZE, BY ENZYME SUPPLEMENTS, 2018-2030 (USD MILLION)
TABLE 282. TURKEY MALABSORPTION SYNDROME MARKET SIZE, BY LACTASE ENZYMES, 2018-2030 (USD MILLION)
TABLE 283. TURKEY MALABSORPTION SYNDROME MARKET SIZE, BY PANCREATIC ENZYMES, 2018-2030 (USD MILLION)
TABLE 284. TURKEY MALABSORPTION SYNDROME MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 285. TURKEY MALABSORPTION SYNDROME MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2030 (USD MILLION)
TABLE 286. TURKEY MALABSORPTION SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 287. TURKEY MALABSORPTION SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 288. TURKEY MALABSORPTION SYNDROME MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 289. ISRAEL MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 290. ISRAEL MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 291. ISRAEL MALABSORPTION SYNDROME MARKET SIZE, BY ENZYME SUPPLEMENTS, 2018-2030 (USD MILLION)
TABLE 292. ISRAEL MALABSORPTION SYNDROME MARKET SIZE, BY LACTASE ENZYMES, 2018-2030 (USD MILLION)
TABLE 293. ISRAEL MALABSORPTION SYNDROME MARKET SIZE, BY PANCREATIC ENZYMES, 2018-2030 (USD MILLION)
TABLE 294. ISRAEL MALABSORPTION SYNDROME MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 295. ISRAEL MALABSORPTION SYNDROME MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2030 (USD MILLION)
TABLE 296. ISRAEL MALABSORPTION SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 297. ISRAEL MALABSORPTION SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 298. ISRAEL MALABSORPTION SYNDROME MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 299. NORWAY MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 300. NORWAY MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 301. NORWAY MALABSORPTION SYNDROME MARKET SIZE, BY ENZYME SUPPLEMENTS, 2018-2030 (USD MILLION)
TABLE 302. NORWAY MALABSORPTION SYNDROME MARKET SIZE, BY LACTASE ENZYMES, 2018-2030 (USD MILLION)
TABLE 303. NORWAY MALABSORPTION SYNDROME MARKET SIZE, BY PANCREATIC ENZYMES, 2018-2030 (USD MILLION)
TABLE 304. NORWAY MALABSORPTION SYNDROME MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 305. NORWAY MALABSORPTION SYNDROME MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2030 (USD MILLION)
TABLE 306. NORWAY MALABSORPTION SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 307. NORWAY MALABSORPTION SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 308. NORWAY MALABSORPTION SYNDROME MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 309. POLAND MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 310. POLAND MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 311. POLAND MALABSORPTION SYNDROME MARKET SIZE, BY ENZYME SUPPLEMENTS, 2018-2030 (USD MILLION)
TABLE 312. POLAND MALABSORPTION SYNDROME MARKET SIZE, BY LACTASE ENZYMES, 2018-2030 (USD MILLION)
TABLE 313. POLAND MALABSORPTION SYNDROME MARKET SIZE, BY PANCREATIC ENZYMES, 2018-2030 (USD MILLION)
TABLE 314. POLAND MALABSORPTION SYNDROME MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 315. POLAND MALABSORPTION SYNDROME MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2030 (USD MILLION)
TABLE 316. POLAND MALABSORPTION SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 317. POLAND MALABSORPTION SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 318. POLAND MALABSORPTION SYNDROME MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 319. SWITZERLAND MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 320. SWITZERLAND MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 321. SWITZERLAND MALABSORPTION SYNDROME MARKET SIZE, BY ENZYME SUPPLEMENTS, 2018-2030 (USD MILLION)
TABLE 322. SWITZERLAND MALABSORPTION SYNDROME MARKET SIZE, BY LACTASE ENZYMES, 2018-2030 (USD MILLION)
TABLE 323. SWITZERLAND MALABSORPTION SYNDROME MARKET SIZE, BY PANCREATIC ENZYMES, 2018-2030 (USD MILLION)
TABLE 324. SWITZERLAND MALABSORPTION SYNDROME MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 325. SWITZERLAND MALABSORPTION SYNDROME MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2030 (USD MILLION)

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Malabsorption Syndrome market report include:
  • AbbVie Inc.
  • Nestlé S.A.
  • Danone S.A.
  • Reckitt Benckiser Group plc
  • Baxter International Inc.
  • Abbott Laboratories
  • Fresenius Kabi AG
  • Siemens Healthineers AG
  • Roche Diagnostics International Ltd.
  • BioMérieux S.A.

Table Information

Report AttributeDetails
No. of Pages193
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 2.63 Billion
Forecasted Market Value ( USD ) by 2030 $ 3.45 Billion
Compound Annual Growth Rate5.5%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Malabsorption Syndrome Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type - Product Image

Malabsorption Syndrome Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type

  • Report
  • 81 Pages
  • Global
From
Short Bowel Syndrome - Epidemiology Forecast - 2034 - Product Image

Short Bowel Syndrome - Epidemiology Forecast - 2034

  • Report
  • 66 Pages
  • Global
From
Short Bowel Syndrome Market by Treatment Type, Product Type, Route of Administration, Distribution Channel, End Use, Patient Age, Etiology - Global Forecast to 2030 - Product Image

Short Bowel Syndrome Market by Treatment Type, Product Type, Route of Administration, Distribution Channel, End Use, Patient Age, Etiology - Global Forecast to 2030

  • Report
  • 186 Pages
  • Global
From
Celiac Disease Treatment Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034 - Product Image

Celiac Disease Treatment Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034

  • Report
  • 130 Pages
  • Global
From
Short Bowel Syndrome (SBS) - Global Strategic Business Report - Product Image

Short Bowel Syndrome (SBS) - Global Strategic Business Report

  • Report
  • 194 Pages
  • Global
From

About the Malabsorption Syndrome Drug Market

Malabsorption Syndrome Drugs are a type of Gastrointestinal Drugs used to treat malabsorption syndrome, a condition in which the body is unable to absorb nutrients from food. These drugs are used to replace the missing nutrients and help the body absorb them. Commonly used drugs include pancreatic enzymes, bile acid sequestrants, and probiotics. Pancreatic enzymes are used to replace the enzymes that the pancreas is unable to produce, while bile acid sequestrants are used to bind bile acids and prevent them from being reabsorbed. Probiotics are used to restore the balance of beneficial bacteria in the gut. Some companies in the Malabsorption Syndrome Drug market include AbbVie, Allergan, AstraZeneca, Bayer, GlaxoSmithKline, Merck, Novartis, Pfizer, and Takeda. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.